EGFR and hepatocellular carcinoma: Recently, novel HCC-specific target molecules such as Glypican-3 (GPC3), EGFR variant III (EGFRvIII), granulin-epithelin precursor (GEP) and AF-20 antigen were discovered and attempts to treat HCC by using the therapeutic antibody targeting these molecules are underway [38–46].